AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Mechanism of Action
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors.
Dosage Overview
Dose Range
300 mcg – 500 mcg
Route
subcutaneous
Frequency
1x daily
Cycle Length
12–24 weeks
Reconstitution
Typical Dosage (Research)
Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg.
Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects.
Considerations for Men & Women
Women: No established sex-specific differences in fat metabolism effects. As a GH fragment, women's generally higher GH sensitivity could mean stronger responses at equivalent doses. Avoid during pregnancy and breastfeeding due to insufficient safety data.
Men: Standard protocols apply. Often used in body composition research. No sex-specific dose adjustments established.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Concentration: 2.5 mg/ml
Volume to inject: 0.12 ml
Syringe units (U-100): 12.0 units
Pre-filled with AOD-9604 defaults. Adjust values as needed.
Side Effects & Risks
Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH.
Limited long-term human data. Failed to receive FDA approval as an anti-obesity drug. Quality and purity concerns with research-grade products.
Who Uses AOD-9604
Those seeking targeted fat loss, athletes and bodybuilders during cutting phases, individuals wanting GH fat-loss benefits without muscle growth effects.
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.